General Information
Sanofi Aventis Schizophrenia 6726
A 24-week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of oral doses of AVE 1625 5, 10, and 30 mg and placebo on top of an established regimen of either olanzapine, risperidone/paliperidone, quetiapine or aripirazole monotherapy in the treatment of Cognitive Impairment in Schizophrenia.
| Protocol | DRI6726 |
|---|---|
| Identifier | DRI6726 |
| UID | a8735a97-a0d1-49c8-ada9-d7f6d9d9aa6a |
| Status | Done - Archived |
| Phase | 3 |
| Category | Schizophrenia / Adult |
| Launch Year | 2008 |
| NCT Number | - |
| Created | 2010-08-03 16:36 |
| Last Updated | 2010-08-03 16:36 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2008-07-01 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2009-11-13 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohaupt, Stephen | SMohaupt | No |
| Recruiter | - | No | |
| Coordinator | - | No | |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Sanofi-Aventis |
|---|---|
| Division | Sanofi-Aventis |
| Team | Sanofi-Aventis |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
